C WorldWide Group Holding A S boosted its position in shares of Shire PLC (NASDAQ:SHPG) by 26.2% in the fourth quarter, HoldingsChannel.com reports. The firm owned 87,322 shares of the biopharmaceutical company’s stock after purchasing an additional 18,103 shares during the period. C WorldWide Group Holding A S’s holdings in Shire were worth $13,545,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Royal Bank of Canada boosted its holdings in shares of Shire by 7.8% in the second quarter. Royal Bank of Canada now owns 45,260 shares of the biopharmaceutical company’s stock valued at $7,481,000 after buying an additional 3,262 shares during the period. Raymond James Financial Services Advisors Inc. boosted its holdings in shares of Shire by 6.2% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 6,492 shares of the biopharmaceutical company’s stock valued at $1,073,000 after buying an additional 381 shares during the period. Sterling Capital Management LLC acquired a new position in shares of Shire in the second quarter valued at approximately $299,000. Verition Fund Management LLC boosted its holdings in shares of Shire by 18.9% in the second quarter. Verition Fund Management LLC now owns 2,967 shares of the biopharmaceutical company’s stock valued at $490,000 after buying an additional 472 shares during the period. Finally, Dynamic Technology Lab Private Ltd acquired a new position in shares of Shire in the second quarter valued at approximately $406,000. Hedge funds and other institutional investors own 20.31% of the company’s stock.

Shares of Shire PLC (NASDAQ SHPG) opened at $127.43 on Friday. The company has a quick ratio of 0.52, a current ratio of 0.98 and a debt-to-equity ratio of 0.55. The company has a market cap of $39,440.00, a price-to-earnings ratio of 24.00, a PEG ratio of 0.70 and a beta of 1.41. Shire PLC has a 1 year low of $123.73 and a 1 year high of $192.15.

Shire (NASDAQ:SHPG) last posted its quarterly earnings results on Wednesday, February 14th. The biopharmaceutical company reported $3.37 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $3.86 by ($0.49). Shire had a return on equity of 14.41% and a net margin of 10.95%. research analysts forecast that Shire PLC will post 15 EPS for the current year.

A number of analysts have recently commented on the stock. Cowen set a $225.00 price objective on shares of Shire and gave the stock a “buy” rating in a research report on Friday, January 5th. Royal Bank of Canada set a $192.00 price objective on shares of Shire and gave the stock a “buy” rating in a research report on Monday, February 5th. BidaskClub lowered shares of Shire from a “hold” rating to a “sell” rating in a research report on Wednesday, January 10th. Piper Jaffray Companies reissued a “hold” rating on shares of Shire in a research report on Wednesday, January 3rd. Finally, Cantor Fitzgerald set a $222.00 price objective on shares of Shire and gave the stock a “buy” rating in a research report on Wednesday, January 3rd. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and nine have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $212.50.

ILLEGAL ACTIVITY WARNING: “C WorldWide Group Holding A S Has $13.55 Million Position in Shire PLC (SHPG)” was posted by Daily Political and is the property of of Daily Political. If you are reading this story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this story can be viewed at https://www.dailypolitical.com/2018/02/10/c-worldwide-group-holding-a-s-has-13-55-million-position-in-shire-plc-shpg.html.

Shire Profile

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).

Institutional Ownership by Quarter for Shire (NASDAQ:SHPG)

Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.